# Dapagliflozin Propanediol (Farxiga)

Source: https://ourhealthnetwork.com/drugs/dapagliflozin-propanediol
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Dapagliflozin Propanediol?

Dapagliflozin Propanediol (brand name: Farxiga) is a sodium-glucose co-transporter 2 (sglt2) inhibitor. It is prescribed to treat diabetes mellitus, type 2. Across the United States, 89,000 doctors prescribe Dapagliflozin to approximately 650,000 Medicare patients.

## Brand names

Farxiga

## Indications

Dapagliflozin Propanediol is prescribed for the treatment of diabetes mellitus and type 2.

## Conditions treated

- [Diabetes Mellitus](https://ourhealthnetwork.com/conditions/diabetes-mellitus)
- [Type 2](https://ourhealthnetwork.com/conditions/type-2)

## Mechanism of action

Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2.

## Drug classification

- Established Pharmacologic Class: sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Route of administration: ORAL

## Common side effects

female genital mycotic infections, fifty percent, nasopharyngitis, urinary tract infections

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)